ARGOS THERAPEUTICS INC 4
4 · ARGOS THERAPEUTICS INC · Filed Feb 12, 2014
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2014-02-12+1,859→ 6,800 total - Conversion
Series D Preferred Stock
2014-02-12−4,941→ 0 total→ Common Stock (4,941 underlying) - Conversion
Common Stock
2014-02-12+4,941→ 4,941 total - Conversion
Series E Preferred Stock
2014-02-12−1,859→ 0 total→ Common Stock (1,859 underlying)
Footnotes (2)
- [F1]Each share of Series D Preferred Stock converted into 0.1667 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series D Preferred Stock has no expiration date.
- [F2]Each share of Series E Preferred Stock converted into 0.1667 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series E Preferred Stock has no expiration date.